Posted by Michael Wonder on 24 Jul 2023
Biocon Biologics announces positive CHMP opinion for Yesafili, biosimilar aflibercept
24 July 2023 - Biocon Biologics today announced that the EMA’s CHMP has issued a positive opinion recommending approval of Yesfili, an aflibercept biosimilar.
Yesafili, an ophthalmology product, is intended for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch vein or central vein), visual impairment due to diabetic macular oedema and visual impairment due to myopic choroidal neovascularisation.
